State Street Corp Enlivex Therapeutics Ltd. Transaction History

State Street Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$3.81 - $8.64 $1,718 - $3,896	451 Added 2.1%	21,887 $99,000
Q1 2022 May 16, 2022	BUY	$4.92 - $6.66 $7,739 - $10,476	1,573 Added 7.92%	21,436 $120,000
Q4 2021 Feb 14, 2022	BUY	$5.81 - $9.73 $7,965 - $13,339	1,371 Added 7.41%	19,863 $124,000
Q3 2021 Nov 15, 2021	BUY	$7.43 - $13.86 $137,395 - $256,299	18,492 New	18,492 $183,000

2.13M

16.1K

3.4K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $23.4M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.